Skip to main content
SpringerLink
Log in

Pro-drug Gene Therapy for Prostate Cancer

  • Conference paper
Gene Therapy

Part of the book series: Ernst Schering Research Foundation Workshop ((SCHERING FOUND,volume 27))

  • 194 Accesses

Abstract

Despite a declining incidence of new cases, prostate cancer remains the most common solid organ malignancy in American men (Landis et al. 1998). In 1998, approximately 184 500 new cases of prostate cancer are predicted, accounting for 29% of all male cancers. Moreover, prostate cancer will account for approximately 39 200 cancer deaths in 1998. This will comprise 13% of all cancer deaths in men, second only to lung cancer (Landis et al. 1998). Curative measures for prostate cancer include radical prostatectomy and radiation therapy; however, patients with locoregional and/or distant spread of disease cannot be cured. Following a radical prostatectomy, patients with positive surgical margins, seminal vesicle involvement and/or positive lymph nodes are at increased risk for disease recurrence and shortened survival (Rosen et al. 1992). From 13% to 70% of patients who undergo a radical prostatec—tomy are clinically understaged and are postoperatively found to have tumor extension outside the prostate (Ohori et al. 1995; Paulson 1994; Trapasso et al. 1994; Walsh et al. 1994; Zeitman et al. 1994; Zincke et al. 1994).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anderson FW (1994) Gene therapy for cancer. Hum Gene Ther 5:1–2

    Article  PubMed  Google Scholar 

  • Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, Srivastava S (1997) Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer 71:377–382

    Article  PubMed  CAS  Google Scholar 

  • Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmann S (1997) Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 50:1007–1015

    Article  PubMed  CAS  Google Scholar 

  • Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen S-H, Woo SLC, Roop DR (1995) Inhibition of melanoma growth by ade-noviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 104:313–317

    Article  PubMed  CAS  Google Scholar 

  • Chen S-H, Chen XHL, Wang Y, Kosai K-I, Finegold MJ, Rich SS, Woo SLC (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577–2581

    Article  PubMed  CAS  Google Scholar 

  • Chen S-H, Shine HD, Goodman JC, Grossman RG, Woo SLC (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91:3054–3057

    Article  PubMed  CAS  Google Scholar 

  • Clayman GL, El-Naggar AK, Roth JA, Zhang W-W, Goepfert H, Taylor DL, Liu T-J (1995) In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1–6

    PubMed  CAS  Google Scholar 

  • Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson RB, Dorr FA (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66 [Suppl]: 1039–1044

    PubMed  CAS  Google Scholar 

  • Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SLC, Thompson TC (1996) Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7:515–523

    Article  PubMed  CAS  Google Scholar 

  • Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW, Thompson TC (1996) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151–5155

    Google Scholar 

  • Elion GB (1983) The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 12:9–17

    Article  PubMed  CAS  Google Scholar 

  • Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, Alebelda SM (1996) Treatment of pleural mesothelioma in an

    Google Scholar 

  • immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7:141–148

    Google Scholar 

  • Elshami AA, Saavedra A, Zhang, H Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM (1996) Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3:85–92

    PubMed  CAS  Google Scholar 

  • Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL (1993) The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274–5283

    PubMed  CAS  Google Scholar 

  • Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5273–5283

    Google Scholar 

  • Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86:1458–1462

    Article  PubMed  CAS  Google Scholar 

  • Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB (1978) Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2- hydroxyethoxymethy) guanine. J Biol Chem 253:8721–8727

    PubMed  CAS  Google Scholar 

  • Hall SJ, Mutchnik SE, Chen S-H, Woo SLC, Thompson TC (1997) Adenovirus mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 70:183–187

    Article  PubMed  CAS  Google Scholar 

  • Hamel W, Magnelli L, Chiarugi VP, Israel MA (1996) Herpes simplex virus thymidine kinase/ganciclovir—mediated apoptotic death of bystander cells. Cancer Res 56:2697–2702

    PubMed  CAS  Google Scholar 

  • Huggins C, Hodges C (1941) Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    CAS  Google Scholar 

  • Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer Stat CA 48:6–29

    Article  CAS  Google Scholar 

  • Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB (1994) Inter-leukin-2 transfected prostate cancer cells generate a local anitumor effect in vivo. Prostate 24:244–251

    Article  PubMed  CAS  Google Scholar 

  • Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control study. Cancer Res 46:5276–5281

    PubMed  CAS  Google Scholar 

  • O’Malley BW Jr, Chen S-H, Schwartz MR, Woo SLC (1995) Adenovirus-me-diated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 55:1080–1085

    PubMed  Google Scholar 

  • Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818–1824

    Article  PubMed  CAS  Google Scholar 

  • Oliver S, Bubley G, Crumpacker C (1985) Inhibition of HSV-transformed murine cells by nucleoside analogs 2’-NDG and 2’-nor-GMP Virology 145:84–93

    Article  PubMed  CAS  Google Scholar 

  • Paulson DF (1994) Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152:1826–1830

    PubMed  CAS  Google Scholar 

  • Perez-Cruet MJ, Trask TW, Chen S-H, Goodman JC, Woo SLC, Grossman RG, Shine HD (1994) Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 39:506–511

    Article  PubMed  CAS  Google Scholar 

  • Ram Z, Walbridge S, Shawker T, Culver KW, Baese RM, Oldfield EH (1994) The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 81:256–260

    Article  PubMed  CAS  Google Scholar 

  • Ramesh R, Marroji AJ, Munshi A, Abboud C, Freeman SM (1996) Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 3:373–384

    PubMed  CAS  Google Scholar 

  • Ramesh R, Marroji AJ, Munshi A, Abboud C, Freeman SM (1996) In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp Hematol 24:829–838

    PubMed  CAS  Google Scholar 

  • Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT (1992) Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148:331

    PubMed  CAS  Google Scholar 

  • Thompson TC, Southgate J, Kitchener G, Land H (1989) Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted model. Cell 56:917–930

    Article  PubMed  CAS  Google Scholar 

  • Trapasso JG, DeKernion JB, Smith RB, Dorey F (1994) Incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821–1825

    PubMed  CAS  Google Scholar 

  • Vieweg J, Rosenthal FM, Bannerji R, Heston WDW, Fair WR, Gansbacher B, Gilboa E (1994) Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54:1760–1765

    PubMed  CAS  Google Scholar 

  • Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228–6234

    PubMed  CAS  Google Scholar 

  • Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following retropubic prostatectomy: results at 10 years. J Urol 152:1831–1836

    PubMed  CAS  Google Scholar 

  • Zeitman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ (1994) Radicai prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43:828–833

    Article  Google Scholar 

  • Zincke H, Oesterling JE, Blute ML, Bergstralh EH, Myers RP, Barrett DM (1994) Long-term (15 years) results after radical prostatectomy for clinically localized (Stage T2c or lower) prostate cancer. J Urol 152:1850–1857

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. L. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. T. Scardino
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

R. E. Sobol K. J. Scanlon E. Nestaas

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Adler, H.L., Scardino, P.T. (1998). Pro-drug Gene Therapy for Prostate Cancer. In: Sobol, R.E., Scanlon, K.J., Nestaas, E. (eds) Gene Therapy. Ernst Schering Research Foundation Workshop, vol 27. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03577-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-03577-1_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-03579-5

  • Online ISBN: 978-3-662-03577-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation